Evaluation of IGFBP-7 DNA methylation changes and serum protein variation in Swedish subjects with and without type 2 diabetes

Clinical Epigenetics

Volumn 5, Issue 1, 2013, Pages

  Gu, Harvest F ^a   Gu, Tianwei ^a   Hilding, Agneta ^a   Zhu, Yiming ^b   Kärvestedt, Lars ^a   Östenson, Claes Göran ^a   Lai, Maode ^b   Kutsukake, Masahiko ^c   Frystyk, Jan ^d,e   Tamura, Kazuhiro ^c   Brismar, Kerstin ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ZHEJIANG UNIVERSITY   (China)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^d AARHUS UNIVERSITY   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

IGF 1; IGFBP 1; IGFBP 7; Insulin; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; INSULIN; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7; PROTEIN VARIANT; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUP; FEMALE; GENE; GENETIC ANALYSIS; HUMAN; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7 GENE; INSULIN RESISTANCE; INSULIN SYNTHESIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PYROSEQUENCING; RADIOIMMUNOASSAY; SWEDISH;

EID: 84893981211     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/1868-7083-5-20     Document Type: Article

References (40)

1. Laron Z: The GH-IGF1 axis and longevity. the paradigm of IGF1 deficiency. Hormones (Athens) 2008, 7(1):24-27.
2. LeRoith D, Yakar S: Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007, 3(3):302-310.
3. Clemmons DR: Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007, 6(10):821-833.
4. Juul A: Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003, 13(4):113-170.
5. Dunger DB, Ong KK, Sandhu MS: Serum insulin-like growth factor-I levels and potential risk of type 2 diabetes. Horm Res 2003, 60(Suppl 3):131-135. (Pubitemid 37548216)
6. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K: Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994, 79(3):872-878.
7. Brismar K, Grill V, Efendic S, Hall K: The insulin-like growth factor binding protein-1 in low and high insulin responders before and during dexamethasone treatment. Metabolism 1991, 40(7):728-732.
8. Hilding A, Brismar K, Degerblad M, Thorén M, Hall K: Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995, 80(9):2646-2652.
9. Domené HM, Hwa V, Argente J, Wit JM, Camacho-Hübner C, Jasper HG, Pozo J, van Duyvenvoorde HA, Yakar S, Fofanova-Gambetti OV, Rosenfeld RG, ALS International Collaborative Group: Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res 2009, 72(3):129-141.
10. Lewitt MS, Hall K, Bang P, Brismar K: Altered response of insulin-like growth factor-binding protein 1 to nutritional deprivation in type 2 diabetes mellitus. Metabolism 2005, 54(3):275-280. (Pubitemid 40250085)
11. Lewitt MS, Hilding A, Ostenson CG, Efendic S, Brismar K, Hall K: Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia 2008, 51 (7):1135-1145.
12. Petersson U, Ostgren CJ, Brudin L, Brismar K, Nilsson PM: Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Söderåkra Cardiovascular Risk Factor Study. Diabetes Metab 2009, 35(3):198-205.
13. Rajwani A, Ezzat V, Smith J, Yuldasheva NY, Duncan ER, Gage M, Cubbon RM, Kahn MB, Imrie H, Abbas A, Viswambharan H, Aziz A, Sukumar P, Vidal-Puig A, Sethi JK, Xuan S, Shah AM, Grant PJ, Porter KE, Kearney MT, Wheatcroft SB: Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis. Diabetes 2012, 61(4):915-924.
14. Oh Y, Nagalla SR, Yamanaka Y, Kim HS, Wilson E, Rosenfeld RG: Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem 1996, 271(48):30322-30325.
15. Yamanaka Y, Wilson EM, Rosenfeld RG, Oh Y: Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem 1997, 272(49):30729-30734. (Pubitemid 27527507)
16. López-Bermejo A, Khosravi J, Fernández-Real JM, Hwa V, Pratt KL, Casamitjana R, Garcia-Gil MM, Rosenfeld RG, Ricart W: Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25). Diabetes 2006, 55(8):2333-2339. (Pubitemid 44743632)
17. López-Bermejo A, Khosravi J, Ricart W, Castro A, Hwa V, Pratt KL, Casamitjana R, Rosenfeld RG, Fernández-Real JM: Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1/MAC25) is linked to endothelial-dependent vasodilation in high-ferritin type 2 diabetes. Diabetes Care 2007, 30(6):1615-1617.
18. Kutsukake M, Ishihara R, Momose K, Isaka K, Itokazu O, Higuma C, Matsutani T, Matsuda A, Sasajima K, Hara T, Tamura K: Circulating IGF-binding protein 7 (IGFBP7) levels are elevated in patients with endometriosis or undergoing diabetic hemodialysis. Reprod Biol Endocrinol 2008, 6:54.
19. Ling C, Groop L: Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 2009, 58(12):2718-2725.
20. Gilbert ER, Liu D: Epigenetics: the missing link to understanding β-cell dysfunction in the pathogenesis of type 2 diabetes. Epigenetics 2012, 7 (8):841-852.
21. Drong AW, Lindgren CM, McCarthy MI: The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther 2012, 92(6):707-715.
22. Ruan W, Xu E, Xu F, Ma Y, Deng H, Huang Q, Lv B, Hu H, Lin J, Cui J, Di M, Dong J, Lai M: IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol Ther 2007, 6(3):354-359. (Pubitemid 47328302)
23. Dimberg J, Hong TT, Skarstedt M, Löfgren S, Zar N, Matussek A: Analysis of APC and IGFBP7 promoter gene methylation in Swedish and Vietnamese colorectal cancer patients. Oncol Lett 2013, 5(1):25-30.
24. Sullivan L, Murphy TM, Barrett C, Loftus B, Thornhill J, Lawler M, Hollywood D, Lynch T, Perry AS: IGFBP7 promoter methylation and gene expression analysis in prostate cancer. J Urol 2012, 188(4):1354-1360.
25. Suzuki M, Shiraishi K, Eguchi A, Ikeda K, Mori T, Yoshimoto K, Ohba Y, Yamada T, Ito T, Baba Y, Baba H: Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer. Oncol Rep 2013, 29(4):1308-1314.
26. Chiacchiera F, Piunti A, Pasini D: Epigenetic methylations and their connections with metabolism. Cell Mol Life Sci 2013, 70(9):1495-1508.
27. Almdal T, Scharling H, Jensen JS, Vestergaard H: Higher prevalence of risk factors for type 2 diabetes mellitus and subsequent higher incidence in men. Eur J Intern Med 2008, J19(1):40-45.
28. Gudbjörnsdottir S, Cederholm J, Nilsson PM, Eliasson B, Steering Committee of the Swedish National Diabetes Register: The national diabetes register in Sweden: an implementation of the St. Vincent declaration for quality improvement in diabetes care. Diabetes Care 2003, 26(4):1270-1276. (Pubitemid 36929284)
29. Ding EL, Song Y, Malik VS, Liu S: Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006, 295(11):1288-1299.
30. Insulin-Like Growth Factor Binding Protein 7. http://www.genecards.org/ cgi-bin/carddisp.pl?gene=IGFBP7&search=IGFBP7.
31. Ziemke F, Mantzoros CS: Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010, 91(1):258S-261S.
32. Wauters M, Van Gaal L: Gender differences in leptin levels and physiology: a role for leptin in human reproduction. J Gend Specif Med 1999, 2(5):46-51.
33. Eriksson AK, Ekbom A, Granath F, Hilding A, Efendic S, Ostenson CG: Psychological distress and risk of pre-diabetes and type 2 diabetes in a prospective study of Swedish middle-aged men and women. Diabet Med 2008, 25(7):834-842.
34. Alberti K, Zimmet P: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539.
35. Romelsjö A, Haglund BJ, Diderichsen F, Hallqvist J, Holland S, Nordström G, Svanström L: Participation of primary health care personnel in the Stockholm Health of the Population Study - a preliminary report. Scand J Prim Health Care Suppl 1988, 1:97-103.
36. Tost J, Dunker J, Gut IG: Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing. Biotechniques 2003, 35(1):152-156. (Pubitemid 36828725)
37. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R: Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003, 35(1):146-150. (Pubitemid 36828724)
38. Herbert V, Lau KS, Gottlieb CW, Bleicher SJ: Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 1965, 25(10):1375-1384.
39. Bang P, Eriksson U, Sara V, Wivall IL, Hall K: Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 1991, 124 (6):620-629.
40. Póvoa G, Roovete A, Hall K: Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh) 1984, 107(4):563-570. (Pubitemid 15216173)